Replimune Group, Inc. (REPL)
| Market Cap | 1.24B+183.9% |
| Revenue (ttm) | n/a |
| Net Income | -297.01M |
| EPS | -3.15 |
| Shares Out | 94.22M |
| PE Ratio | n/a |
| Forward PE | -7.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,647,247 |
| Open | 13.14 |
| Previous Close | 13.25 |
| Day's Range | 13.02 - 13.60 |
| 52-Week Range | 1.50 - 16.33 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 19.50(+47.73%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$REPL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in REPL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by REPL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
REPL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New REPL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to REPL from public contracts
Source: USAspending.gov
REPL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from REPL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score